A registry date is not a readout: five ways ClinicalTrials.gov misleads a CI team
ClinicalTrials.gov is the best free source of competitive evidence in drug development. Read naively, it overstates crowding, misdates readouts and hides failures. Here are five traps, each sized on today's registry, with the rule that disarms it.
The registry is not wrong. It is a set of sponsor declarations, each with its own date, rules and blind spots, and every one of the traps below comes from reading those declarations as if they were facts about today. The numbers above size each trap on the registry as it stands this week.
1. A multinational trial is one trial, not twelve
Take the 48 industry Phase 2â3 atopic dermatitis trials recruiting today. Across the 22 countries we checked, they produce 125 country entries, because every trial counts once in every country where it has a site.
48 trials become 125 country entries
That is correct when the question is "where are the sites?" and badly wrong when the question is "how many competing programmes?". The rule: name the unit. A country chart counts trial-country pairs; print the distinct n next to it, every time.
2. Phase 1/2 and Phase 2/3 trials count twice
Right now 2,031 active industry trials are registered as Phase 1/2 and 390 as Phase 2/3. In a phase breakdown each one lands in two columns unless someone decides otherwise. Two analysts with the same data and different defaults will produce different pipelines.
The rule: pick one convention per exhibit and state it in the footer. Comphas places a multi-phase trial at its highest phase on a bullseye and counts it in each cell on a heatmap, and says which it did.
3. "Recruiting" is what the sponsor last said
Status is a claim with a date attached. 975 of 8,694 recruiting industry trials (11.2%) carry a primary completion date more than six months in the past. 1,994 (22.9%) have not had their status verified in over a year.
The registry ages: share of trials affected by each trap
The rule: show the status-verified date beside the status, and flag every trial whose date has passed while its status has not moved.
4. Primary completion is not a readout
Primary completion marks the end of data collection for the primary endpoint. Nobody outside the sponsor has seen a result at that point. Of 1,540 completed industry Phase 3 trials whose primary completion fell between January 2022 and June 2024, 997 have results posted on ClinicalTrials.gov; 543 do not.
A gap is a question, not an accusation. US results reporting applies to "applicable clinical trials" under FDAAA 801 and its final rule (42 CFR Part 11), and many trials outside its scope report through journals, press releases or the EU Clinical Trials Information System instead. The rule: model a readout as primary completion plus a reporting lag, and check publications and other registries before calling a readout missed.
5. Stopped trials hide inside the totals
27 of 278 Phase 3 atopic dermatitis trials on record were terminated, withdrawn or suspended. Leave them in a pipeline count and the field looks stronger than it is. Drop them silently and you lose the most informative signal in the dataset: why someone walked away.
The rule: split stopped trials out, then read the "why stopped" field. Business, safety and enrolment reasons each mean something different to a competitor.
None of this makes the registry wrong. It makes it a source that needs a method. In Comphas every number answers three questions: what was counted, on what date, from which source. See how evidence is frozen and recorded.
Run it yourself
Every number above came from a query you can repeat. Ask the registry the same question for your own indication; the answer is drawn live, with its source and query time.
AI reads your question into filters; every number comes straight from the ClinicalTrials.gov API at the moment you ask.
Method and queries
ClinicalTrials.gov API v2, pulled 17 Oct 2026. All counts use the ClinicalTrials.gov API v2 with countTotal. Industry = lead sponsor class INDUSTRY. Active = recruiting, not yet recruiting, active not recruiting, enrolling by invitation.
- Trap 1: recruiting, interventional, industry, Phase 2 or 3, condition "atopic dermatitis"; country counts via LocationCountry for 22 countries.
- Trap 2: active, interventional, industry, Phase = PHASE1 AND PHASE2 (and PHASE2 AND PHASE3), all conditions.
- Trap 3: recruiting, interventional, industry; PrimaryCompletionDate on or before 16 Apr 2026; StatusVerifiedDate on or before 16 Oct 2025.
- Trap 4: completed, interventional, industry, Phase 3, PrimaryCompletionDate 1 Jan 2022â30 Jun 2024; HasResults = true.
- Trap 5: interventional Phase 3 atopic dermatitis, all sponsors and years; terminated, withdrawn or suspended.
Turn a registry question into a defensible decision.
Bring one live programme to an 8-week pilot. We build the board, freeze the evidence and run the decision session with you.